The Effects of Mirror Therapy on Upper Extremity in Stroke Patients

This study is currently recruiting participants.
Verified November 2012 by Taipei Medical University Hospital
Sponsor:
Information provided by (Responsible Party):
Taipei Medical University Hospital
ClinicalTrials.gov Identifier:
NCT01656876
First received: July 27, 2012
Last updated: November 28, 2012
Last verified: November 2012

July 27, 2012
November 28, 2012
September 2010
March 2013   (final data collection date for primary outcome measure)
  • Fugl-Meyer Assessment (FMA) [ Time Frame: Baseline, change from baseline in FMA at 4 weeks, change from baseline in FMA at 16 weeks, change from baseline in FMA at 28 weeks ] [ Designated as safety issue: No ]
    The upper-extremity subscale of the FMA contains 33 items to assess motor impairment. Each item is scored on a 3-point ordinal scale (0-cannot perform, 1-performs partially, 2-performs fully and correctly). The sub-score of a proximal shoulder/elbow (0-42) and a distal hand/wrist (0-24) will be also calculated to investigate the treatment effects on separate upper extremity elements.
  • Wolf Motor Function Test (WMFT) [ Time Frame: Baseline, change from baseline in WMFT at 4 weeks, change from baseline in WMFT at 16 weeks, change from baseline in WMFT at 28 weeks ] [ Designated as safety issue: No ]
    • The WMFT composed of 3 parts: Time, Functional ability, and Strength
    • Includes 15 function-based tasks and 2 strength based tasks
    • Performance time is referred to as WMFT-TIME
    • Functional ability is referred to as WMFT-FAS
    • Items 1-6 involve timed functional tasks, items 7-14 are measures of strength, and the remaining 9 items consist of analyzing movement quality when completing various tasks.
    • Examiner should test the less affected upper extremity followed by the most affected side.
    • Uses a 6-point ordinal scale
    • "0" = "does not attempt with the involved arm" to
    • "5" = "arm does participate; movement appears to be normal."
    • Maximum score is 75
    • Lower scores are indicative of lower functioning levels
    • WMFT-TIME allows 120 seconds per task
  • Accelerometers [ Time Frame: Baseline, change from baseline in accelerometers at 4 weeks, change from baseline in accelerometers at 16 weeks, change from baseline in accelerometers at 28 weeks ] [ Designated as safety issue: No ]
    The accelerometers are used to provide a direct and objective measure of the amount of the impaired arm movement outside the laboratory. Acceleration is sampled at 10 Hz and summed over a user- specified epoch. The recording epoch in this study is 2 seconds; recording capacity is approximately 72 hours. A "threshold-filter" will be applied to the raw recordings to obtain an accurate measure of the duration of arm movement.
  • revised Nottingham Sensory Assessment (rNSA) [ Time Frame: Baseline, change from baseline in rNSA at 4 weeks, change from baseline in rNSA at 16 weeks, change from baseline in rNSA at 28 weeks ] [ Designated as safety issue: No ]
    The rNSA examines the sensory function of the affected arm and includes tactile sensation (0=Absent, 1=Impaired, 2=Normal), proprioception (0=Absent, 1=Appreciation of movement sense, 2=Direction of movement sense, 3=Joint position sense), and stereognosis (0=Absent, 1=Impaired, 2=Normal) subtests.
Same as current
Complete list of historical versions of study NCT01656876 on ClinicalTrials.gov Archive Site
  • Kinematic analyses [ Time Frame: Baseline, change from baseline in kinematic parameters at 4 weeks ] [ Designated as safety issue: No ]
    A 7-camera motion-analysis system (VICON MX, Oxford Metrics Inc., Oxford, UK) was used. The variables of reaction time (second), movement time (second), total displacement (mm), peak velocity (mm/second), percentage of peak velocity, joint recruitments (degree), and maximum shoulder and elbow cross-correlation were collected.
  • Motor Activity Log (MAL) [ Time Frame: Baseline, change from baseline in MAL at 4 weeks, change from baseline in MAL at 16 weeks, change from baseline in MAL at 28 weeks ] [ Designated as safety issue: No ]
    The MAL is a semi-structured interview of patients to assess the amount of use (AOU) and quality of movement (QOM) of the affected upper extremity in 30 important daily activities using a 6-point ordinal scale. Higher scores indicate superior amount and quality of use in affected upper extremity.
  • Semmes-Weinstein monofilaments [ Time Frame: Baseline, change from baseline in Semmes-Weistein monofilaments at 4 weeks, change from baseline in Semmes-Weistein monofilaments at 16 weeks, change from baseline in Semmes-Weistein monofilaments at 28 weeks ] [ Designated as safety issue: No ]
    The Semmes-Weinstein monofilaments is used for measuring diminishing and returning cutaneous sensation.A nylon 'string' is specifically calibrated in stiffness to represent a baseline level of sensation that can be considered 'the line' between having neuropathy and having normal sensation.
  • Functional Independence Measure (FIM) [ Time Frame: Baseline, change from baseline in FIM at 4 weeks, change from baseline in FIM at 16 weeks, change from baseline in FIM at 28 weeks ] [ Designated as safety issue: No ]
    The FIM consists of 18 items grouped into 6 subscales. Each item is rated from 1 to 7 (max. score 126) based on the required level of assistance to perform the tasks.
  • Stroke Impact Scale version 3.0 (SIS 3.0) [ Time Frame: Baseline, change from baseline in SIS at 4 weeks, change from baseline in SIS at 16 weeks, change from baseline in SIS at 28 weeks ] [ Designated as safety issue: No ]
    The SIS is a stroke-specific instrument of health related quality of life and contains 59 items measuring 8 domains. Items are rated on a 5- point Likert scale with lower scores indicate greater difficulty in task completion during the past week. Aggregate scores, ranges from 0 to 100, are generated for each domain.
  • 8-OHdG [ Time Frame: Baseline, change from baseline in 8-OHDG at 4 weeks, change from baseline in 8-OHDG at 16 weeks, change from baseline in 8-OHDG at 28 weeks ] [ Designated as safety issue: No ]
    Urinary 8-OHdG is a stable and integral biomarker of oxidative DNA damage.About 10 mL to 15 mL urine samples of the patients will be collected in the centrifugal tubes before and after rehabilitation interventions. The samples will be transported with dry ice under 4°C and preserved in a -80°C refrigerator before analysis. A highly sensitive and selective method, using isotope- dilution liquid chromatography with tandem mass spectrometry (LC/MS/MS), will be used to determine the urinary 8-OHdG levels.
Same as current
Not Provided
Not Provided
 
The Effects of Mirror Therapy on Upper Extremity in Stroke Patients
The Effects of Mirror Therapy on Upper Extremity in Stroke Patients

The purpose of this study is to compare treatment efficacy of mirror therapy (MT), mirror therapy combining mesh glove (MG+MT) stimulation, and controlled treatment (CT) in people with stroke.

55% to 75% of people after stroke have a paretic arm that causes motor impairment. Among novel rehabilitation interventions, MT was found to be beneficial and comparatively low-cost. MT reduced motor impairment possibly in part of recruiting the premotor cortex or balancing the neural activation within the primary motor cortex toward the affected hemisphere. However, the benefits in certain aspects of outcomes are under debate. Another treatment, MG, can be used to normalize muscle tone, suppress muscle spasticity, enhance residual volitional activity of hand and arm, or even increasing walking speed. In addition, providing MG stimulation might result in plastic changes in the primary motor cortex, and induced a long-lasting modulated effect on motor cortical excitability. The possible mechanism of brain plasticity underlying MG is collective with the mechanism behind the MT. Adding MG to MT might augment the cortical reorganization. In sum, combining MT with MG may supplement the disadvantage or uncertain effects of MT and broaden the benefited outcomes.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Factorial Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
Cerebrovascular Accident
  • Behavioral: Mirror box training
    This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the visual feedback of the unaffected upper extremity reflected by the mirror.
    Other Name: MT
  • Other: mesh glove stimulation
    The MG is a two-channel electrical stimulator providing synchronous or reciprocal sensory stimulation with variant amplitudes.
    Other Name: MG
  • Behavioral: conventional intervention
    Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach
    Other Name: CI
  • Experimental: Mirror therapy
    mirror box training with or without sham mesh glove stimulation
    Intervention: Behavioral: Mirror box training
  • Experimental: Mirror therapy + Mesh glove stimulation
    Mirror therapy combined with mesh glove stimulation
    Interventions:
    • Behavioral: Mirror box training
    • Other: mesh glove stimulation
  • Active Comparator: Controlled intervention
    conventional interventions
    Intervention: Behavioral: conventional intervention
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
60
March 2013
March 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • The onset duration more than 3 months
  • Demonstration of Brunnstrom stage equal to or above stage III of the affected upper extremity
  • No serious cognitive deficits (a score of more than 24 on the Mini Mental State Exam)
  • No serious visual and visual-perception impairments
  • No concurrent participation in other drug or rehabilitation research
  • No serious attention deficits
  • No excessive spasticity in any of the joints of the affected UL exclusion criteria

Exclusion Criteria:

  • Exhibit physician determined major medical problems or poor physical conditions that would interfere with participation
  • Excessive pain in any joint that might limit participation
Both
20 Years to 75 Years
No
Contact: Ching-yi Wu, ScD 886-3-2118800 ext 5761 cywu@mail.cgu.edu.tw
Taiwan
 
NCT01656876
CRC-09-10-08
No
Taipei Medical University Hospital
Taipei Medical University Hospital
Not Provided
Principal Investigator: Tsan-hon Liou, PhD Shuang-Ho Hospital, Taipei Medical University
Principal Investigator: Ching-yi Wu, ScD Department of Occupational Therapy, College of Medicine, Chang Gung University
Principal Investigator: Keh-chung Lin, ScD School of Occupational Therapy, College of Medicine, National Taiwan University
Taipei Medical University Hospital
November 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP